Source: Annual Congress 2007 - Diagnostic tests and treatment in non cystic fibrosis bronchiectasis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. A. Anwar, C. Ward, S. Bourke, G. Afolabi, P. Middleton, R. Rutherford (North Shields, Newcastle upon Tyne, United Kingdom). Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis. Eur Respir J 2007; 30: Suppl. 51, 3177

Member's Comments

No comment yet.

Related content which might interest you: Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Role of non-cystic fibrosis bronchiectasis in hospitalized patients with acute exacerbation of COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 Assessing response to treatment of exacerbations of bronchiectasis in adults Source: Eur Respir J 2009; 33: 312-318 Year: 2009 Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis Source: Eur Respir J 2012; 40: 61-66 Year: 2012 Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Symptom duration and the lung clearance index in children with cystic fibrosis and pulmonary exacerbations Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019 Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations Source: Eur Respir J 2015; 46: 1055-1064 Year: 2015 HRCT features in patients with severe asthma and non-cystic fibrosis bronchiectasis. Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Exercise capacity in patients with cystic fibrosis vs non-cystic fibrosis bronchiectasis Source: International Congress 2018 – Mechanisms that underlie exercise limitation in various respiratory diseases Year: 2018 Sputum bacterial concentrations and exacerbations of non cystic fibrosis bronchiectasis Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008 Non-cystic fibrosis bronchiectasis in children Source: Virtual Congress 2021 – Posters in paediatric bronchology Year: 2021 Prevalence of non-cystic fibrosis bronchiectasis in patients with severe asthma: a real-life study Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Longitudinal decline in FEV1 in an adult non-cystic fibrosis bronchiectasis cohort Source: Eur Respir J 2007; 30: Suppl. 51, 529s Year: 2007 Pulmonary arterial enlargement is a predictor of higher risk of exacerbations in non-cystic fibrosis bronchiectasis patients Source: Virtual Congress 2021 – Bronchiectasis Year: 2021 Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 The low dose macrolides for prevention of exacerbations in non-CF bronchiectasis Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Inhaled steroids in children with non-cystic fibrosis bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 392s Year: 2004 Clinical and functional profile of patients with non-cystic fibrosis bronchiectasis according to the presence of chronic bronchial infection Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis Source: ERJ Open Res, 4 (1) 00111-2017; 10.1183/23120541.00111-2017 Year: 2018